Shane Kannarr, OD, overviews results from a phase 4, multicenter, prospective, open-label trial that evaluated the impact of concomitant use of PFHO during contact lens wear.
Feature|Articles|July 6, 2026
FDA decisions in eye care: A first-half 2026 recap
Author(s)Abigail Lewis, Content Intern
Fact checked by: Jordana Joy, Editor
A summary of major FDA approvals and CRLs in eye care from the first half of 2026.
Advertisement
Advertisement
The first half of 2026 has delivered a notable mix of FDA approvals, complete response letters, and regulatory milestones across several therapeutic areas relevant to optometric practice. From first-in-class presbyopia drops and EDOF contact lenses to new tools for thyroid eye disease and ongoing setbacks in dry eye, the regulatory landscape has moved quickly. Below is a summary of the major decisions optometrists should be aware of heading into the second half of the year.
Related to this article
Magdalena Stec, OD, FAAO; Noreen Shaikh, OD, FAAO; Huizi Kelly Yin, OD, FAAO; and Brenda Bohnsack, MD, PhD, detail their AAOpt 2026 session in Anaheim, California.
Lloyd Williams, MD, PhD, discusses rising cataract blindness and low-cost surgery in conflict zones for World Sight Day.
Jacob Lang, OD, FAAO, details his AAOPt 2026 poster presentation "Rapid and Durable Redness Relief with a Novel Brimonidine Tartrate Ophthalmic Solution Containing Hyaluronic Acid."
Amber Carissa "A.C." Flynn details a case in her AAOpt 2026 poster that demonstrates successful ocular surface optimization for a patient with several eye conditions.
Kevin Chan, OD, MS, FAAO, FBCLA, IACMM, stated in his Rapid Fire lecture that high myopes shouldn't be counted out of orthokeratology treatment.
Mohammad Rafieetary, OD, FAAO, FORS, DipABO, ABCMO, details his AAOpt 2026 presentation "Photobiomodulation in Age-Related Macular Degeneration: Evidence, Mechanisms, and Clinical Integration."
Magdalena Stec, OD, FAAO, and Noreen Shaikh, OD, MEd, FAAO, gave an overview of current evidence-based myopia control treatments in part of their AAOpt 2026 session.
Advertisement
Advertisement